Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015437 · ClinicalTrials.gov registry record · Phase 2
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
A Phase 2 study of Healthy Subjects, sponsored by Cerus Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT07015437 is a Phase 2 study of Healthy Subjects that is actively recruiting participants, run by Cerus Corporation. The registered enrollment target is 70 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07015437, a Phase 2 study of Healthy Subjects, is actively recruiting participants, sponsored by Cerus Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this trial is to assess the post-infusion viability of INTERCEPT RBCs by measuring the 24-hour post-infusion recovery and lifespan of autologous RBCs prepared with the INTERCEPT Blood System for RBC with AS-1 after 35 days post collection storage in comparison to untreated AS-1 RBCs stored for 35 days.
Conditions Studied
Interventions
- DEVICE INTERCEPT Blood System for RBCs
- OTHER Infusion of autologous radiolabeled RBCs
Study Locations (2)
Ohio
- Hoxworth Blood Center - Cincinnati
Virginia
- American Red Cross Research Laboratory - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2026-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07015437
The ClinicalTrials.gov registry entry for NCT07015437 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (45% lower). The listed sponsor is Cerus Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which INTERCEPT Blood System for RBCs is the first listed.
NCT07015437 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT07015437 about?
NCT07015437 is a clinical study titled "A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1". The objective of this trial is to assess the post-infusion viability of INTERCEPT RBCs by measuring the 24-hour post-infusion recovery and lifespan of autologous RBCs prepared with the INTERCEPT Blood System for RBC with AS-1 after 35 days post collection storage in comparison to untreated AS-1 RBCs...
What is the current status of trial NCT07015437?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-09-19. Estimated completion is 2026-10-15.
What conditions does trial NCT07015437 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT07015437?
The interventions under investigation include: INTERCEPT Blood System for RBCs (DEVICE), Infusion of autologous radiolabeled RBCs (OTHER).
Who is sponsoring clinical trial NCT07015437?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015437 being conducted?
This trial has 2 study locations across Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
COMPLETED · Phase 2
-
Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth
COMPLETED · Phase 2
-
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
RECRUITING
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
Radiocaine Safety Study In Healthy Human Subjects
RECRUITING · Early Phase 1
-
Optimizing Ultrasound-induced Anti-inflammation in Human Subjects
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.